Answer
Physicochemical data suggest Exblifep passes into human milk, and excretion in rat milk is demonstrated; infant risk cannot be excluded, so a decision is needed whether to stop breastfeeding or discontinue or avoid Exblifep, weighing breastfeeding benefits for the child against treatment benefits for the mother.
Sources for this answer
- EXBLIFEP 2 g/0.5 g powder for concentrate for solution for infusionADVANZ Pharma · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 1Document updated
Sources checked